Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv)
-
Published:2022-12-08
Issue:5
Volume:128
Page:877-885
-
ISSN:0007-0920
-
Container-title:British Journal of Cancer
-
language:en
-
Short-container-title:Br J Cancer
Author:
Orsi Giulia, Cavaliere Alessandro, Tortora GiampaoloORCID, Lonardi SaraORCID, Macchini Marina, Di Marco Mariacristina, Giordano Guido, Vasile Enrico, Scartozzi MarioORCID, Bozzarelli Silvia, Noventa Silvia, Rodriquenz Maria Grazia, Militello Anna Maria, Rapposelli Ilario Giovanni, Garajova IngridORCID, De Lorenzo Stefania, Merelli Barbara, Bittoni Alessandro, Salvatore Lisa, Procaccio Letizia, Paratore Chiara, Spallanzani Andrea, Peretti Umberto, Niger MonicaORCID, Giommoni Elisa, Bernardini Ilaria, Tamburini Emiliano, Bernardino Katia, Forti Laura, Valente Maria Maddalena, Cascinu Stefano, Milella Michele, Reni MicheleORCID
Funder
MyEverest ONLUS MyEVerest ONLUS This study was partially supported by MyEverest ONLUS (no grant number).
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Reference27 articles.
1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33. 2. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–21. 3. Park W, Chawla A, O’Reilly EM. Pancreatic cancer: a review. JAMA. 2021;326:851–62. 4. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703. 5. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.
|
|